Common Requirements and Industry Practices for Biological Reagents in In Vitro Diagnostic Raw Material Quality Management

1. Understanding the Quality Attributes of Biological Reagents from Application Scenarios

Biological reagents play a fundamental role in in vitro diagnostics, life science research, and biopharmaceutical development. Their scope typically includes antigens, antibodies, enzymes, nucleic acids, vectors, cell culture media, buffers, substrates, and various molecular biology tool reagents. Different application scenarios have different requirements for biological reagents. For example, antibodies used in immunoturbidimetric assays focus on affinity, specificity, and lot-to-lot consistency; enzymes used in fluorescence quantitative PCR emphasize amplification efficiency, fidelity, and tolerance to inhibitors; serum or culture media used for cell culture require assessment of endotoxins, sterility levels, and growth-promoting performance. Therefore, in the establishment of a quality system, all biological reagents cannot be measured by a single indicator; instead, a tiered and classified quality control plan should be established based on the intended use.

In the research and development and production of in vitro diagnostic reagents, biological reagents often serve as core raw materials that directly affect the sensitivity, specificity, stability, and linear range of the finished reagent. In some projects, differences in raw material sources may also lead to deviations in the traceability of calibrators. Therefore, quality management at the raw material end is often moved forward to the stages of supplier evaluation, incoming inspection, and process validation, rather than tracing back only after problems occur in the finished product. The industry generally requires the establishment of supplier admission, change control, and re-evaluation mechanisms to ensure that biological reagents remain traceable and reproducible throughout their life cycle.

2. Key Quality Indicators and Common Testing Methods

Quality evaluation of biological reagents requires the integration of multiple dimensions, including physicochemical properties, biological activity, purity, and contaminant control. Common testing items may include protein purity, nucleic acid purity, enzyme activity, antibody titer, host cell protein residues, nucleic acid residues, endotoxins, sterility or microbial limits, pH, osmolality, appearance, and fill volume. Different products have different emphases in testing items due to differences in form and use. For example, recombinant protein raw materials generally focus on purity, molecular weight, biological activity, and endotoxin levels; antibody raw materials also require evaluation of specificity, cross-reactivity, and lot-to-lot consistency; molecular biology enzyme reagents require testing for nuclease residues, amplification efficiency, and fidelity.

At the methodological level, protein reagents are commonly analyzed by means such as SDS-PAGE, Western blot, enzyme-linked immunosorbent assay, or high-performance liquid chromatography; nucleic acid reagents can be evaluated by ultraviolet spectrophotometry, agarose gel electrophoresis, fluorescence quantitative PCR, or capillary electrophoresis; cell-related biological reagents require combination with sterility testing, mycoplasma testing, endotoxin testing, and cell proliferation or functional assays. It should be noted that any single method is difficult to fully reflect the quality of biological reagents. In industry practice, orthogonal or complementary method combinations are often used, with appropriate reference standards, control materials, and trend analysis.

3. Lot-to-Lot Consistency and Stability Management

Lot-to-lot consistency is one of the core concerns of in vitro diagnostic and research users regarding biological reagents. Because biological reagents are mostly derived from organisms or expressed through bioengineering, a certain degree of natural variability exists. If the lot-to-lot differences in key raw materials are too large, it may lead to calibration curve shifts, increased background, or decreased sensitivity in the finished kit. For this reason, quality management generally reduces variation through strict process control, tiered use of raw materials, blending lot strategies, key performance verification, and statistical process control. Some companies establish internal reference materials or standard substances to confirm the key performance of each raw material lot and conduct comparability analysis with historical lots.

Stability management cannot be ignored either. Biological reagents are usually sensitive to temperature, light, pH, repeated freeze-thaw cycles, and other conditions. Generally, appropriate storage conditions, shelf life, and transportation methods are determined based on accelerated stability, long-term stability, transport stability, and in-use stability studies. Common storage temperatures include 2~8°C, -20°C, -80°C, or liquid nitrogen, depending on product characteristics and research results. The user end should also establish cold chain monitoring and temperature deviation handling procedures to avoid activity loss caused by improper storage. Stability data should not be simply understood as such, but should be comprehensively judged in combination with factors such as actual packaging, buffer system, and protective agents.

4. Biosafety and Compliance Requirements

Biological reagents may involve human-derived, animal-derived, microbial-derived, or recombinant expression systems, so biosafety management is an important part of industry standards. For raw materials of blood origin, tissue origin, or cell origin, attention should be paid to donor screening, virus inactivation, pathogen testing, and source compliance; for recombinant proteins or antibodies, attention should be paid to the expression host, vector, resistance genes, and residual host components.If in vitro diagnostic raw materials are used for the production of medical devices, they shall also comply with the requirements of relevant regulations regarding raw material quality control, traceability, and change management.

At the documentation and records level, suppliers are generally required to provide quality inspection reports, safety data sheets, certificates of origin, animal-derived declarations, declarations of no infectious diseases, or declarations of conformity. Some products also require information on quality management system certifications such as ISO 9001 or ISO 13485. When introducing new materials, purchasers typically conduct risk assessments, small-scale trial validation, pilot-scale scale-up, and stability studies, and, when necessary, on-site supplier audits. The goal of the entire process is not to pursue an absolute statement of zero defects, but to establish a closed-loop risk management system that is identifiable, controllable, and traceable.

V. Common Misconceptions and Directions for Improvement in Industry Practice

In practice, some teams tend to regard price as the primary or even sole criterion for purchasing biological reagents, while neglecting critical performance validation and technical support. Low-priced raw materials may be deficient in sensitivity, batch-to-batch consistency, or long-term supply stability, thereby increasing later-stage debugging and after-sales costs. Another common misconception is relying entirely on quality inspection reports provided by suppliers, lacking incoming inspection and periodic re-evaluation. It is recommended to set differentiated inspection strategies according to material risk levels: batch-by-batch inspection for critical raw materials, periodic sampling inspection for general raw materials, and for low-risk materials, acceptance based on supplier reports combined with visual inspection.

In the future, as the in vitro diagnostics and life science tools industries continue to raise quality requirements, the quality management of biological reagents will place greater emphasis on data-driven approaches, standardization, and full life cycle traceability. Enterprises can enhance supply chain resilience by establishing raw material databases, trend analysis of critical quality attributes, and supplier collaboration mechanisms. For research users, standardized validation processes should also be gradually developed to reduce experimental uncertainty caused by reagent variability. Overall, incorporating biological reagents into a systematic quality system is a fundamental step in ensuring downstream product performance and experimental reproducibility.